ReviewAdvanced drug delivery reviews2019
Optimizing Advances in Nanoparticle Delivery for Cancer Immunotherapy.
Review in Advanced drug delivery reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Nano-Delivery of Immunogenic Cell Death Inducers and Immune Checkpoint Blockade Agents: Single-Nanostructure Strategies for Enhancing Immunotherapy.Pharmaceutics · 2024Review
- Nanosystem Delivers Senescence Activators and Immunomodulators to Combat Liver Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Responsive nanosystems for targeted therapy of ulcerative colitis: Current practices and future perspectives.Drug delivery · 2023Article
- Nanomedicine in Lung Cancer Immunotherapy.Frontiers in bioengineering and biotechnology · 2023Review
- Three-dimensional (3D) scaffolds as powerful weapons for tumor immunotherapy.Bioactive materials · 2022Review
- Recent Advances in Functionalized Nanoparticles in Cancer Theranostics.Nanomaterials (Basel, Switzerland) · 2022Review
- Protease-controlled secretion and display of intercellular signals.Nature communications · 2022Article
- Recent advances in nanomedicines for photodynamic therapy (PDT)-driven cancer immunotherapy.Theranostics · 2022Review
- Biomaterial nanocarrier-driven mechanisms to modulate anti-tumor immunity.Current opinion in biomedical engineering · 2021Article
- Iron oxide nanoparticles for immune cell labeling and cancer immunotherapy.Nanoscale horizons · 2021Review
- Biological drug and drug delivery-mediated immunotherapy.Acta pharmaceutica Sinica. B · 2021Review
- Enhancing Cancer Immunotherapy Treatment Goals by Using Nanoparticle Delivery System.International journal of nanomedicine · 2021Review
- Near-Infrared Photoactivatable Immunomodulatory Nanoparticles for Combinational Immunotherapy of Cancer.Frontiers in chemistry · 2021Review
- Engineering Prodrug Nanomedicine for Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Review
- Tackling TAMs for Cancer Immunotherapy: It's Nano Time.Trends in pharmacological sciences · 2020Review
- Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment.Acta pharmacologica Sinica · 2020Review
- Modeling of Nanotherapy Response as a Function of the Tumor Microenvironment: Focus on Liver Metastasis.Frontiers in bioengineering and biotechnology · 2020Review
- Stimuli-Responsive Polymeric Nanosystem for Colon Specific Drug Delivery.Advanced pharmaceutical bulletin · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cancer immunotherapy is one of the fastest growing and most promising fields in clinical oncology. T-cell checkpoint inhibitors are revolutionizing the management of advanced cancers including non-small cell lung cancer and melanoma. Unfortunately, many common cancers are not responsive to these drugs and resistance remains problematic. A growing number of novel cancer immunotherapies have been discovered but their clinical translation has been limited by shortcomings of conventional drug delivery. Immune signaling is tightly-regulated and often requires simultaneous or near-simultaneous activation of multiple signals in specific subpopulations of immune cells. Nucleic acid therapies, which require intact intracellular delivery, are among the most promising approaches to modulate the tumor microenvironment to a pro-immunogenic phenotype. Advanced nanomedicines can be precisely engineered to overcome many of these limitations and appear well-poised to enable the clinical translation of promising cancer immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.